Related Experiment Video
Updated: Jun 27, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Alcohol use reduction program in methadone maintained individuals with hepatitis C virus infection
Adeline Nyamathi1, Viviane de Castro, Donna McNeese-Smith
1University of California, Los Angeles, School of Nursing, Los Angeles, California, USA. anyamath@sonnet.ucla.edu
Journal of Addictive Diseases
|December 2, 2008
Summary
Methadone-maintained clients face barriers to alcohol abuse treatment, including provider insensitivity. Engaging them requires motivational strategies and support to reduce alcohol use.
Area of Science:
- Addiction Medicine
- Behavioral Health
- Public Health
Background:
- Methadone maintenance is a key treatment for opioid use disorder.
- Co-occurring alcohol abuse presents significant challenges for this population.
- Effective engagement strategies are crucial for successful treatment outcomes.
Purpose of the Study:
- To identify personal and social barriers faced by methadone-maintained clients seeking alcohol abuse treatment.
- To explore strategies for engaging these clients in treatment programs.
- To understand factors facilitating or hindering treatment seeking and adherence.
Main Methods:
- Qualitative research design.
- Semi-structured focus groups conducted with 41 methadone-maintained clients in Los Angeles.
- Content analysis of recorded and transcribed sessions.
Main Results:
- Healthcare provider attitudes, knowledge, and sensitivity are critical for client engagement.
- Facilitators include incentives and various forms of support (emotional, financial, material).
- Barriers include lack of provider knowledge and insensitivity regarding resource acquisition.
- Personal motivation is a key attribute for successful behavioral change.
Conclusions:
- Motivational enhancement strategies by healthcare providers can improve engagement.
- Comprehensive support systems are vital for successful alcohol reduction in methadone-maintained clients.
- Addressing provider knowledge gaps and insensitivity is essential for effective treatment.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...